Cargando…
Immunological heterogeneity informs estimation of the durability of vaccine protection
Deciphering the properties of vaccines against an emerging pathogen is essential for optimizing immunization strategies. Early after vaccine roll-out, however, uncertainties about vaccine immunity raise the question of how much time is needed to estimate these properties, particularly the durability...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Societ
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131131/ https://www.ncbi.nlm.nih.gov/pubmed/35611620 http://dx.doi.org/10.1098/rsif.2022.0070 |
Sumario: | Deciphering the properties of vaccines against an emerging pathogen is essential for optimizing immunization strategies. Early after vaccine roll-out, however, uncertainties about vaccine immunity raise the question of how much time is needed to estimate these properties, particularly the durability of vaccine protection. Here we designed a simulation study, based on a generic transmission model of vaccination, to simulate the impact of a breadth of vaccines with different mean (range: 10 months–2 years) and variability (coefficient of variation range: 50–100%) of the duration of protection. Focusing on the dynamics of SARS-CoV-2 in the year after start of mass immunization in Germany as a case study, we then assessed how confidently the duration of protection could be estimated under a range of epidemiological scenarios. We found that lower mean and higher heterogeneity facilitated estimation of the duration of vaccine protection. Across the vaccines tested, rapid waning and high heterogeneity permitted complete identification of the duration of protection; by contrast, slow waning and low heterogeneity allowed only estimation of the fraction of vaccinees with rapid loss of immunity. These findings suggest that limited epidemiological data can inform the duration of vaccine immunity. More generally, they highlight the need to carefully consider immunological heterogeneity when designing transmission models to evaluate vaccines. |
---|